3-4-diaminocyclobut-3-ene-1-2-dione and Retinal-Degeneration

3-4-diaminocyclobut-3-ene-1-2-dione has been researched along with Retinal-Degeneration* in 1 studies

Other Studies

1 other study(ies) available for 3-4-diaminocyclobut-3-ene-1-2-dione and Retinal-Degeneration

ArticleYear
Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promoting β-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells.
    ChemMedChem, 2022, 12-16, Volume: 17, Issue:24

    The glycogen synthase kinase 3β (GSK-3β) is a ubiquitous enzyme that is a validated target for the development of potential therapeutics useful in several diseases including retinal degeneration. Aiming at developing an innovative class of allosteric inhibitors of GSK-3β potentially useful for retinal degeneration, we explored the class of squaramides. The developed compounds (6 a-l) were obtained through a nontoxic one-pot synthetic protocol, which employs low-cost goods and avoids any purification step. Ethanol was used as the reaction solvent, simultaneously allowing the pure reaction products' recovery (by precipitation). Out of this set of squaramides, 6 j stood out, from computational and enzymatic converging data, as an ATP non-competitive inhibitor of GSK-3β of micromolar potency. When engaged in cellular studies using retinal pigment epithelial cells (ARPE-19) transfected with a luciferase reporter gene under the control of T-cell factor/lymphoid enhancer factor (TCF/LEF) binding sites, 6 j was able to dose-dependently induce β-catenin nuclear accumulation, as shown by the increased luciferase activity at a concentration of 2.5 μM.

    Topics: beta Catenin; Epithelial Cells; Glycogen Synthase Kinase 3 beta; Humans; Luciferases; Quinine; Retinal Degeneration; Retinal Pigment Epithelium; Signal Transduction; TCF Transcription Factors

2022